Secondary myeloid neoplasms after CD19 CAR T therapy in patients with refractory/relapsed B-cell lymphoma: Case series and review of literature

BACKGROUND: Several chimeric antigen receptor T cells (CAR T) targeting CD19 have induced profound and prolonged remission for refractory/relapsed (R/R) B-cell lymphoma. The risk of secondary malignancies, especially myeloid neoplasms, is of particular concern in the CAR T community, which still rem...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Aiqi, Zhao, Mingzhe, Qian, Wenbin, Liang, Aibin, Li, Ping, Liu, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9880439/
https://www.ncbi.nlm.nih.gov/pubmed/36713414
http://dx.doi.org/10.3389/fimmu.2022.1063986

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9880439/
https://www.ncbi.nlm.nih.gov/pubmed/36713414
http://dx.doi.org/10.3389/fimmu.2022.1063986

Ejemplares similares